Patents by Inventor Catherine Jorand

Catherine Jorand has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted pyrazoles as IRAK inhibitors
    Patent number: 10314841
    Abstract: The present invention provides compounds of Formula (II) for the treatment of cancer, rheumatoid arthritis and other diseases.
    Type: Grant
    Filed: January 9, 2015
    Date of Patent: June 11, 2019
    Assignee: Merck Patent GmbH
    Inventors: Catherine Jorand-Lebrun, Reinaldo Jones
  • Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof
    Patent number: 10259795
    Abstract: The invention provides ?-amino esters of a hydroxypropylthiazolidine carboxamide derivative, (2S)-3-([1,1?-biphenyl]-4-ylsulfonyl)-N-[(1S)-3-hydroxy-1-phenylpropyl]-1,3-thiazolidine-2-carboxamide, as well as salts and crystal polymorphs thereof, that can be used to inhibit prostaglandin F receptor. The invention further encompasses methods of treating disorders such as pre-term labor at the early gestational stage by the administration of these substances to a patient in need of treatment.
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: April 16, 2019
    Assignee: Merck Serono S.A.
    Inventors: Patrick Naxos Page, Matthias Schwarz, Catherine Jorand-Lebrun, Anna Quattropani, Vincent Pomel
  • ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF
    Publication number: 20190000812
    Abstract: The invention provides pharmaceutical compositions comprising a compound of formula (I) or (II) and an additional therapeutic agent Also provided is the HCI salt and crystalline form of the compound of formula (I). The compounds inhibit the prostaglandin F receptor (PGF2alpha) and thus useful in the treatment of disorders such as preterm labor at the early gestational stage.
    Type: Application
    Filed: January 4, 2017
    Publication date: January 3, 2019
    Inventors: Patrick Naxos PAGE, Matthias SCHWARZ, Catherine JORAND-LEBRUN, Anna QUATTROPANI, Vincent POMEL, Ernest LOUMAYE, Oliver POHL, Jean-Pierre GOTTELAND
  • Macrocyclic pyridazinone derivatives
    Patent number: 10064861
    Abstract: A compound of formula (I) is provided: wherein R1, R2, R3, R4, L and Z have the meaning given in the claims. Further provided is the prophylaxis and treatment of diseases with the compound of formula (I).
    Type: Grant
    Filed: November 30, 2016
    Date of Patent: September 4, 2018
    Assignee: Merck Patent GmbH
    Inventors: Catherine Jorand-Lebrun, Santosh Kulkarni, Serge Christmann-Franck
  • Heteroaryl compounds as IRAK inhibitors and uses thereof
    Patent number: 10059701
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: August 28, 2018
    Assignee: Merck Patent GmbH
    Inventors: Catherine Jorand-Lebrun, Ruoxi Lan, Austin Chen, Ryan C. Clark
  • HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF
    Publication number: 20180237426
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.
    Type: Application
    Filed: April 23, 2018
    Publication date: August 23, 2018
    Inventors: Catherine JORAND-LEBRUN, Ruoxi LAN, Austin CHEN, Ryan C. Clark
  • HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF
    Publication number: 20180237413
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.
    Type: Application
    Filed: April 17, 2018
    Publication date: August 23, 2018
    Inventors: Catherine JORAND-LEBRUN, Ruoxi LAN, Austin CHEN, Ryan C. CLARK
  • COMPOUNDS FOR THE INHIBITION OF CYCLOPHILINS AND USES THEREOF
    Publication number: 20180230162
    Abstract: The present invention relates to compounds, and pharmaceutically acceptable compositions thereof, useful as inhibitors of cyclophilins, and for the treatment of cyclophilin-related disorders.
    Type: Application
    Filed: April 16, 2018
    Publication date: August 16, 2018
    Inventors: Catherine JORAND-LEBRUN, Theresa L. JOHNSON, Ulrich GRAEDLER, Xuliang JIANG, Santosh KULKARNI
  • Heteroaryl compounds as IRAK inhibitors and uses thereof
    Patent number: 10030013
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.
    Type: Grant
    Filed: September 12, 2017
    Date of Patent: July 24, 2018
    Assignee: Merck Patent GmbH
    Inventors: Catherine Jorand-Lebrun, Reinaldo Jones, Annie Cho Won, Ngan Nguyen, Theresa L. Johnson, Lizbeth Celeste Deselm, Kausik Panda
  • ALPHA-AMINO ESTERS OF HYDROXYPROPYLTHIAZOLIDINE CARBOXAMIDE DERIVATIVE AND SALT FORM, CRYSTAL POLYMORPH THEREOF
    Publication number: 20180201591
    Abstract: The invention provides ?-amino esters of a hydroxypropylthiazolidine carboxamide derivative, (2S)-3-([1,1?-biphenyl]-4-ylsulfonyl)-N-[(1S)-3-hydroxy-1-phenylpropyl]-1,3-thiazolidine-2-carboxamide, as well as salts and crystal polymorphs thereof, that can be used to inhibit prostaglandin F receptor. The invention further encompasses methods of treating disorders such as pre-term labor at the early gestational stage by the administration of these substances to a patient in need of treatment.
    Type: Application
    Filed: October 10, 2017
    Publication date: July 19, 2018
    Inventors: Patrick Naxos PAGE, Matthias SCHWARZ, Catherine JORAND-LEBRUN, Anna QUATTROPANI, Vincent POMEL
  • PYRIMIDINE PYRAZOLYL DERIVATIVES AND THEIR USE AS IRAK INHIBITORS
    Publication number: 20180169094
    Abstract: The present invention provides compounds of Formula (II) for the treatment of cancer, rheumatoid arthritis and other diseases.
    Type: Application
    Filed: January 9, 2015
    Publication date: June 21, 2018
    Inventors: Catherine JORAND-LEBRUN, Reinaldo JONES
  • Compounds for the inhibition of cyclophilins and uses thereof
    Patent number: 9975902
    Abstract: The present invention relates to compounds, and pharmaceutically acceptable compositions thereof, useful as inhibitors of cyclophilins, and for the treatment of cyclophilin-related disorders.
    Type: Grant
    Filed: March 30, 2017
    Date of Patent: May 22, 2018
    Assignee: Merck Patent GmbH
    Inventors: Catherine Jorand-Lebrun, Theresa L. Johnson, Ulrich Graedler, Xuliang Jiang, Santosh Kulkarni
  • Heteroaryl compounds as IRAK inhibitors and uses thereof
    Patent number: 9969710
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: May 15, 2018
    Assignee: Merck Patent GmbH
    Inventors: Catherine Jorand-Lebrun, Ruoxi Lan, Austin Chen, Ryan C. Clark
  • HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF
    Publication number: 20180002327
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.
    Type: Application
    Filed: September 12, 2017
    Publication date: January 4, 2018
    Inventors: Catherine JORAND-LEBRUN, Reinaldo JONES, Annie Cho WON, Ngan NGUYEN, Theresa L. JOHNSON, Lizbeth Celeste DESELM, Kausik PANDA
  • Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof
    Patent number: 9834528
    Abstract: The invention provides ?-amino esters of a hydroxypropylthiazolidine carboxamide derivative, (2S)-3-([1,1?-biphenyl]-4-ylsulfonyl)-N-[(1S)-3-hydroxy-1-phenylpropyl]-1,3-thiazolidine-2-carboxamide, as well as salts and crystal polymorph s thereof, that can be used to inhibit prostaglandin F receptor. The invention further encompasses methods of treating disorders such as pre-term labor at the early gestational stage by the administration of these substances to a patient in need of treatment.
    Type: Grant
    Filed: August 8, 2016
    Date of Patent: December 5, 2017
    Assignee: Merck Serono S.A.
    Inventors: Patrick Naxos Page, Matthias Schwarz, Catherine Jorand-Lebrun, Anna Quattropani, Vincent Pomel
  • Macrocyclic compounds as IRAK1/4 inhibitors and uses thereof
    Patent number: 9815836
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.
    Type: Grant
    Filed: June 12, 2017
    Date of Patent: November 14, 2017
    Assignee: Merck Patent GmbH
    Inventors: Xiaoling Chen, Henry Yu, Ruoxi Lan, Catherine Jorand-Lebrun, Theresa L. Johnson, Andreas Goutopoulos
  • Heteroaryl compounds as IRAK inhibitors and uses thereof
    Patent number: 9790221
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: October 17, 2017
    Assignee: Merck Patent GmbH
    Inventors: Catherine Jorand-Lebrun, Reinaldo Jones, Annie Cho Won, Ngan Nguyen, Theresa L. Johnson, Lizbeth Celeste Deselm, Kausik Panda
  • COMPOUNDS FOR THE INHIBITION OF CYCLOPHILINS AND USES THEREOF
    Publication number: 20170283427
    Abstract: The present invention relates to compounds, and pharmaceutically acceptable compositions thereof, useful as inhibitors of cyclophilins, and for the treatment of cyclophilin-related disorders.
    Type: Application
    Filed: March 30, 2017
    Publication date: October 5, 2017
    Inventors: Catherine JORAND-LEBRUN, Theresa L. JOHNSON, Ulrich GRAEDLER, Xuliang JIANG, Santosh KULKARNI
  • COMPOUNDS FOR THE INHIBITION OF CYCLOPHILINS AND USES THEREOF
    Publication number: 20170283425
    Abstract: The present invention relates to compounds, and pharmaceutically acceptable compositions thereof, useful as inhibitors of cyclophilins, and for the treatment of cyclophilin-related disorders.
    Type: Application
    Filed: March 30, 2017
    Publication date: October 5, 2017
    Inventors: Catherine JORAND-LEBRUN, Theresa L. JOHNSON, Ulrich GRAEDLER, Xuliang JIANG, Didier ROCHE, Hugues LEMOINE, Marine GILARDONE
  • COMPOUNDS FOR THE INHIBITION OF CYCLOPHILINS AND USES THEREOF
    Publication number: 20170283426
    Abstract: The present invention relates to compounds, and pharmaceutically acceptable compositions thereof, useful as inhibitors of cyclophilins, and for the treatment of cyclophilin-related disorders.
    Type: Application
    Filed: March 30, 2017
    Publication date: October 5, 2017
    Inventors: Catherine JORAND-LEBRUN, Theresa L. JOHNSON, Ulrich GRAEDLER, Xuliang JIANG, Didier ROCHE, Hugues LEMOINE, Marine GILARDONE